Enfuvirtide

At a glance

Overview

Enfuvirtide blocks a step in HIV entry that differs from reverse-transcriptase, protease, and integrase inhibition. This made it important when patients had limited treatment options because of resistance to older drug classes. It was administered subcutaneously as part of combination antiretroviral therapy, not as a cure or stand-alone treatment. Frequent injection-site reactions and the burden of injections influenced its practical use. Genentech announced the end of US marketing and commercial distribution on February 28, 2025. A knowledge-base listing should preserve its established evidence and history while making clear that it is no longer a routine available US commercial option.

Supporting sources [1] [2] [3] [4]

How it works

Enfuvirtide binds the HIV-1 envelope protein gp41 and interferes with the conformational changes required for fusion of viral and host-cell membranes. This prevents entry into susceptible cells. It does not eradicate integrated viral reservoirs, and resistance can emerge if the surrounding regimen lacks sufficient activity. The mechanism is antiviral rather than a nonspecific stimulation or suppression of the human immune system.

Supporting sources [1] [2] [3] [4]

Its established HIV role

The historical FDA label specifies combination treatment for treatment-experienced patients with ongoing HIV-1 replication despite antiretroviral therapy. An active background regimen is important to achieve durable suppression and limit resistance. Enfuvirtide was not approved as monotherapy, prevention of all viral infections, or treatment of immune deficiency unrelated to HIV.

Supporting sources [1]

The TORO clinical program

In TORO 1, adding enfuvirtide to an optimized background regimen produced greater viral-load reductions and immunologic improvement than the background regimen alone in heavily treatment-experienced patients. The outcome was improved control of HIV replication, not eradication of infection. The trial population differs from people starting contemporary first-line HIV therapy.

Supporting sources [2]

Injection reactions and serious precautions

Injection-site pain, nodules, and inflammation were very common. Systemic hypersensitivity and bacterial pneumonia were important warnings in the label. Because combination therapy and underlying HIV disease influence adverse events, the full regimen and immune status matter when interpreting risk or replacing a discontinued component.

Supporting sources [1]

What changed in availability?

Genentech’s formal notice ended all US marketing and commercial distribution of Fuzeon on February 28, 2025. That is a commercial-availability change and should not be rewritten as evidence that its original antiviral efficacy was disproved. Historical product information remains useful for understanding prior treatment and resistance histories.

Supporting sources [3]

Does discontinuation erase its established HIV evidence?

No. The clinical evidence for enfuvirtide as part of combination antiretroviral treatment remains meaningful, but current commercial availability is a separate question. The US distribution discontinuation should be considered when discussing options. Research material bearing the same name is not a substitute for an approved finished medicine.

Supporting sources [1] [3]